Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.61−0.06 (-8.25%)
Close on Nov 13, 2026Market cap $354.83KP/E –Yield –
Virax Biolabs EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$12.64. The highest annual figure on record is -$12.64 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$12.64 | – |
| FY2025 | Mar 31, 2025 | -$40.62 | – |
| FY2024 | Mar 31, 2024 | -$83.90 | – |
| FY2023 | Mar 31, 2023 | -$128.25 | – |
| FY2022 | Mar 31, 2022 | -$44.75 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?